pat-sm6 receives orphan drug designationfor mm, page-60

Orphan drug designation will entitle PAT-SM6 to ten years of market exclusivity for multiple myeloma; scientific advice and protocol assistance by the EMA to optimise drug development; regulatory assistance and facilitated access to the Centralised Procedure for marketing approval; numerous financial incentives and fee reductions for regulatory activities; and access to grant funding schemes. - See more at: http://www.biospectrumasia.com/biospectrum/news/195347/ema-patrys-cancer-drug-orphan-status#.UjrWhIYbDTp

ahpigsy i seriously dont think te market has factored this news in yet and what its worth is to pab

malmanu i love this quote from Stuart Roberts a man who knows his bios

Is there an Australian angle to this story? If you go to the web site for the ASX-listed cancer antibody developer Patrys you can find some research there suggesting that the cancer antibody field has plenty of room for other companies to create serious shareholder value. Worth doing some homework on.
http://ozbiobuzz.blogspot.com.au/2013/08/hello-and-welcome-to-australian.html